Autopsy report · NCT04318444

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)

“The Institutional Review Board closed the study”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 3 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Columbia University

Sponsor type

University, hospital or other

Conditions

COVID-19; Corona Virus Infection

Interventions

Hydroxychloroquine; Placebo oral tablet

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  “The study was closed due to the end of funding.” (71% match in meaning)
• Changes in Bone Turnover With Increased Incretin Hormone Exposure
  “Study closed by sponsor. Funding ended.” (67% match in meaning)
• Team Based Equity Conscious Telemedicine Approach to Hypertension
  “closed because we were funded for another similar study” (65% match in meaning)
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (65% match in meaning)
• SHIFT: Studying HIV Immunology After Fecal Transplant
  “The study closed because of shifting research priorities and interests.” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.